drugset / Trial / NCT00134459
Study Evaluating Bifeprunox in Bipolar Depression
Phase 3
Completed
434 enrolled
Wyeth is now a wholly owned subsidiary of Pfizer
Solvay Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
Timeline
- Start
- 2005-06
- Primary completion
- 2006-05
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bifeprunox | Small molecule | — | — |